SCHEMBL5855879

SCHEMBL5855879

CCc1oc(-c2ccc(C)cc2)nc1CCCCCl

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 12/20 0.56
PPARA Q07869 12/20 0.56
TARBP2 Q15633 2/20 0.40
PPARD Q03181 2/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
TSHR P16473 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1929665 0.84 PPARG (0.47) PPARGPPARATARBP2PPARDKDM4E
SCHEMBL18095687 0.81 PPARG (0.54) PPARGPPARATARBP2PPARDKDM4E
SCHEMBL5855826 0.81 PPARG (0.54) PPARGPPARATARBP2PPARDALDH1A1
SCHEMBL1048319 0.78 PPARG (0.47) PPARGPPARATARBP2PPARDKDM4E
SCHEMBL4928762 0.78 PPARG (0.43) PPARGPPARATARBP2PPARDKDM4E
SCHEMBL5855946 0.77 PPARG (0.56) PPARGPPARATARBP2PPARDALDH1A1
SCHEMBL5855943 0.75 PPARG (0.53) PPARGPPARATARBP2PPARDALDH1A1
Butane SCHEMBL5855937 0.74 PPARG (0.55) PPARGPPARATARBP2PPARDSMN1; SMN2
SCHEMBL5855939 0.73 PPARA (0.54) PPARGPPARATARBP2PPARD
SCHEMBL5856967 0.73 PPARA (1.00) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
CN-1238347-C Heterocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2006-01-25 CN disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
CN-1430612-A Hete rocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2003-07-16 CN disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB PPARG 393/4885PPARA 464/4885TARBP2 3609/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE PPARG 603/4885PPARA 579/4885TARBP2 3787/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARG 701/4885PPARA 660/4885TARBP2 4113/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARG 701/4885PPARA 660/4885TARBP2 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.